Flamel Technologies (FLML) -19% premarket after agreeing to acquire specialty drug maker Eclat...

|By:, SA News Editor

Flamel Technologies (FLML) -19% premarket after agreeing to acquire specialty drug maker Eclat Pharmaceuticals in a debt-and-warrant deal and named Eclat's chief executive to replace its own CEO.